ReadYourDNA

Glatiramer Acetate (Copaxone)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Glatiramer Acetate

What it is

Glatiramer acetate is a mix of synthetic protein fragments that resemble myelin basic protein, part of the protective coating of nerves. It is thought to divert the immune attack in multiple sclerosis and shift immune cells towards a calmer, regulatory state. It is injected under the skin daily or three times a week for relapsing multiple sclerosis. It is sold as Copaxone and as generics.

How genes come into it

As a peptide mixture broken down at the injection site, glatiramer is not handled by drug-processing enzymes. Studies have looked at immune genes such as HLA-DRB1*15:01 (the main inherited risk factor for multiple sclerosis), CTLA4, TGFB1 and CCR5 for who responds. The findings come from single or a few studies, and there is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Glatiramer Acetate. Upload your DNA file to see which of these rows apply to you.

Rated evidence (3 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

rs12459996: Level 3. Toxicity. 1.

rs1056854: Level 3. Toxicity. 1.

rs75041078: Level 3. Toxicity. 1.

Response (11 findings)

Studies of how well it worked in people carrying a variant.

CCR5 rs333: Allele del is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele GTCAGTATCAATTCTGGAAGAATTTCCAGACA.

CLEC16A rs6498169: Allele A is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.

EOMES rs2371108: Allele T is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.

HLA-DRB1 HLA-DRB1*15:01: HLA-DRB1 *15:01 is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Mayzent (Immunomodulators)

Tecfidera (Immunomodulators)

Revlimid (Immunomodulators)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com